Spyre Therapeutics legal chief sells 28,933 shares

Q: What SYRE stock options did Heidy King-Jones exercise?

She exercised options for 28,933 common shares at $14.50 per share on October 1, 2026. The reported stock-option position after the exercise was 482,478 underlying shares, and the option’s expiration date was September 1, 2033.

The sale prices were weighted averages; the transaction-specific price ranges were $88.63 to $89.53, $89.96 to $90.95, $91.10 to $92.09, $92.12 to $93.09, and $93.17 to $93.75.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Legal Officer and Corporate Secretary Heidy King-Jones exercised options for 28,933 common shares at $14.50 per share on October 1, 2026, then sold 28,933 shares in five transactions under a Rule 10b5-1 trading plan adopted April 16, 2026. The sales had weighted-average prices of $89.24 (400 shares), $90.35 (16,605), $91.35 (7,228), $92.70 (2,100), and $93.46 (2,600) per share. The reported post-exercise stock-option position was 482,478 underlying shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 28,933 shares ($2.21M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider King-Jones Heidy

Role See Remarks

Sold 28,933 shs ($2.63M)

Approx. gross sale proceeds $2.63M

Approx. exercise cost $420K

Approx. pre-tax spread $2.21M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F7}	28,933	$0.00	$0.00
Exercise	Common Stock ^F1	28,933	$14.50	$420K
Sale	Common Stock ^{F1, F2}	400	$89.24	$36K
Sale	Common Stock ^{F1, F3}	16,605	$90.35	$1.50M
Sale	Common Stock ^{F1, F4}	7,228	$91.35	$660K
Sale	Common Stock ^{F1, F5}	2,100	$92.70	$195K
Sale	Common Stock ^{F1, F6}	2,600	$93.46	$243K

Holdings After Transaction: Stock Option (Right to Buy) — 482,478 contracts (Direct); Common Stock — 2,845 shares (Direct)

Footnotes (7)

F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F7. This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Key Figures

Options exercised: 28,933 shares Option exercise price: $14.50 per share Reported post-exercise stock-option position: 482,478 underlying shares +5 more

8 metrics

Options exercised 28,933 shares October 1, 2026

Option exercise price $14.50 per share Options exercised October 1, 2026

Reported post-exercise stock-option position 482,478 underlying shares Following the October 1, 2026 exercise

Weighted-average sale price (400 shares) $89.24 per share October 1, 2026

Weighted-average sale price (16,605 shares) $90.35 per share October 1, 2026

Weighted-average sale price (7,228 shares) $91.35 per share October 1, 2026

Weighted-average sale price (2,100 shares) $92.70 per share October 1, 2026

Weighted-average sale price (2,600 shares) $93.46 per share October 1, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, vesting, exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vesting technical

"the remaining three quarters vesting in monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercisable financial

"became exercisable on September 1, 2024"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SYRE shares did Heidy King-Jones sell, and at what prices?

Heidy King-Jones, Spyre Therapeutics’ Chief Legal Officer and Corporate Secretary, sold 28,933 common shares on October 1, 2026, in five transactions pursuant to a Rule 10b5-1 plan adopted April 16, 2026. Their weighted-average prices were $89.24 (400 shares), $90.35 (16,605), $91.35 (7,228), $92.70 (2,100), and $93.46 (2,600) per share.

What SYRE stock options did Heidy King-Jones exercise?

She exercised options for 28,933 common shares at $14.50 per share on October 1, 2026. The reported stock-option position after the exercise was 482,478 underlying shares, and the option’s expiration date was September 1, 2033.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/02/2026 - 09:30 PM Accepted by SEC EDGAR 10/02/2026 - 09:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

King-Jones Heidy

(Last)

(First)

(Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M⁽¹⁾		28,933	A	$14.5	31,778	D
Common Stock	10/01/2026		S⁽¹⁾		400	D	$89.24⁽²⁾	31,378	D
Common Stock	10/01/2026		S⁽¹⁾		16,605	D	$90.35⁽³⁾	14,773	D
Common Stock	10/01/2026		S⁽¹⁾		7,228	D	$91.35⁽⁴⁾	7,545	D
Common Stock	10/01/2026		S⁽¹⁾		2,100	D	$92.7⁽⁵⁾	5,445	D
Common Stock	10/01/2026		S⁽¹⁾		2,600	D	$93.46⁽⁶⁾	2,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$14.5	10/01/2026		M⁽¹⁾			28,933	⁽⁷⁾	09/01/2033	Common Stock	28,933	$0	482,478	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

7. This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Heidy King-Jones	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR